About
52North is a biotechnology company based in Oakham, England, founded in 2018. The company specializes in research and development of innovative healthcare solutions, particularly aimed at improving the lives of cancer patients. Its flagship product, Neutrocheck®, is a fully integrated clinical and AI-powered medical device that offers a low-cost, at-home finger-prick blood test. This test quickly assesses the risk of neutropenic sepsis, a serious complication for chemotherapy patients, allowing for convenient health monitoring and earlier intervention. The digital platform associated with Neutrocheck® utilizes artificial intelligence to enhance predictions of patient risk and outcomes. 52North is committed to health equity and aims to make advanced medical technology accessible to improve patient care. The company has secured significant funding to support its mission, including a £1 million round in 2022 and a $6 million financing round in 2024. Its primary customers include cancer patients, healthcare providers, and health systems, all benefiting from improved monitoring and reduced costs in patient care.
Technologies
Keywords
Company Information
-
Employees 25
-
Founded 2018
-
Annual Revenue $1000000
-
Total Funding $8876807
Location
Cambridge, England, United Kingdom
